Rescue Intravitreal Aflibercept Injection
ApprovedUNKNOWN 0 watching 0 views this week๐ฅ Hot
84
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Neovascular Polypoidal Choroidal Vasculopathy
Conditions
Neovascular Polypoidal Choroidal Vasculopathy
Trial Timeline
Mar 1, 2014 โ Mar 1, 2016
NCT ID
NCT02092532About Rescue Intravitreal Aflibercept Injection
Rescue Intravitreal Aflibercept Injection is a approved stage product being developed by Regeneron Pharmaceuticals for Neovascular Polypoidal Choroidal Vasculopathy. The current trial status is unknown. This product is registered under clinical trial identifier NCT02092532. Target conditions include Neovascular Polypoidal Choroidal Vasculopathy.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02092532 | Approved | UNKNOWN |
Competing Products
20 competing products in Neovascular Polypoidal Choroidal Vasculopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CLS-AX + Anti-VEGF | Clearside Biomedical | Phase 1/2 | 33 |
| CLS-AX + Aflibercept | Clearside Biomedical | Phase 2 | 44 |
| Eylea + ALT-L9 | Alteogen | Phase 1 | 33 |
| UBX1325 injection 50 ฮผL + EYLEAยฎ (aflibercept) Injection 2 mg (0.05mL) | Unity Biotechnology | Phase 2 | 44 |
| DS-7080a + Ranibizumab | Daiichi Sankyo | Phase 1 | 33 |
| Avacincaptad Pegol | Astellas Pharma | Phase 1 | 33 |
| Avacincaptad Pegol + Avastin + Lucentis + Eylea | Astellas Pharma | Phase 2 | 52 |
| Avacincaptad Pegol + Lucentis | Astellas Pharma | Phase 2 | 52 |
| KHK4951 + Aflibercept Injection | Kyowa Kirin | Phase 2 | 52 |
| Surabgene Lomparvovec (ABBV-RGX-314) + Ranibizumab Control | AbbVie | Phase 3 | 77 |
| Ranibizumab + Local Steroid + Topical Steroid | AbbVie | Phase 2 | 52 |
| Lucentis | Novartis | Pre-clinical | 23 |
| ranibizumab | Novartis | Phase 3 | 77 |
| Brolucizumab | Novartis | Pre-clinical | 23 |
| ranibizumab | Novartis | Approved | 85 |
| brolucizumab + ranibizumab + aflibercept | Novartis | Pre-clinical | 23 |
| Beovu | Novartis | Pre-clinical | 23 |
| Ranibizumab | Novartis | Phase 3 | 77 |
| Ranibizumab | Novartis | Approved | 85 |
| Intraviteal Ranibizumab 0.5mg | Novartis | Approved | 85 |